ANI Pharmaceuticals introduces Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg
1 July 2020 -

United States-based ANI Pharmaceuticals, Incorporated (Nasdaq:ANIP) has launched its Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg, it was reported on Tuesday.

The product is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia.

Patrick Walsh, ANI's interim president and CEO, said, 'This is our sixth generic product launch in 2020. The launch represents an important milestone for ANI in the integration of our Oakville, Canada manufacturing site, acquired in August 2018. Mexiletine is the first new ANI product launch from the Oakville site. I congratulate the team in Oakville on achieving this milestone; we look forward to additional ANI product launches from this plant in the future.'